Top Markets
#1 Helium Helium +58.68%
#2 TENDIES TENDIES +35.43%
#3 Pons Pons +15.18%
#4 Biconomy Biconomy +12.83%
#5 Songbird Songbird +12.74%
#6 UnifAI Network UnifAI Network +10.88%
#7 OSK OSK +9.90%
#8 MarsCoin MarsCoin +9.68%
#9 Seeker Seeker +9.03%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +8.88%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
HK inno.N Corporation HK inno.N Corporation

HK inno.N Corporation

195940
Rank in Stocks #10328
Founded in 1984 and headquartered in Cheongju-si, South Korea, HK inno.N... Founded in 1984 and headquartered in Cheongju-si, South Korea, HK inno.N Corporation operates as a pharmaceutical enterprise. The company boasts a comprehensive portfolio of prescription medications designed to address a wide array of medical conditions. These include treatments for various infectious diseases, such as those caused by gram-positive and gram-negative bacteria, vancomycin-resistant Enterococcus faecium, acute bacterial sinusitis, bronchitis, and pneumonia. Their therapeutic offerings also extend to chronic illnesses like anemia, diabetes, hypertension (including cases with dyslipidemia), and hypercholesterolemia (covering primary and homozygous familial types), alongside solutions for hemodialysis. The firm develops drugs for gastrointestinal disorders such as GERD, EE, NERD, GU, and H. Pylori infections. In the oncology sector, HK inno.N provides treatments for non-small cell lung cancer, colorectal cancer, and both pleural and general mesothelioma. Additionally, they offer nutritional and intravenous therapeutic solutions. Beyond pharmaceuticals, the corporation supplies health and wellness products, including hangover relief drinks, ready-to-drink beverages, health supplements, functional foods, and active pharmaceutical ingredients. Its beauty division markets products under the bewants, ScalpMed, and KLEDERMA RX brands. The company maintains an international presence, exporting its diverse range of products to markets across Japan, Southeast Asia, Latin America, Europe, and the Middle East.
Share Price
$30.18
Last synced: 2026-08-28
Market Cap
$855.10M
Change (1 day)
1.39%
Change (1 year)
-12.84%
Country
KR
Trade HK inno.N Corporation (195940)

Category

Healthcare
P/E ratio for HK inno.N Corporation (195940)
P/E ratio as of 2026 TTM: 0
According to HK inno.N Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for HK inno.N Corporation from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
HCA Healthcare, Inc. HCA Healthcare, Inc.
HCA Healthcare, Inc.
HCA.US
 13.51 -
US
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA
FRE.DE
 - -
DE
Dr. Sulaiman Al Habib Medical Services Group Company Dr. Sulaiman Al Habib Medical Services Group Company
Dr. Sulaiman Al Habib Medical Services Group Company
4013.SR
 33.05 -
SA
Tenet Healthcare Corporation Tenet Healthcare Corporation
Tenet Healthcare Corporation
THC.US
 10.26 -
US
IHH Healthcare Berhad IHH Healthcare Berhad
IHH Healthcare Berhad
5225.KL
 - -
MY
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.